HomeNewsBusinessCompaniesSitting on AC inventory, waiting for lockdown to lift: Carrier Midea India MD

Sitting on AC inventory, waiting for lockdown to lift: Carrier Midea India MD

Carrier Midea is also awaiting a nod from the government to resume servicing and maintenance activity of air conditioners for its customers

April 21, 2020 / 20:32 IST
Story continues below Advertisement

The air conditioner (ACs) industry, which sees a majority of sales in the March to June period, is waiting for the novel coronavirus, or COVID-19, lockdown to be lifted to drive sales and begin servicing. In an interaction with Moneycontrol, Krishan Sachdev, Managing Director, Carrier Midea India, said the company is sitting on AC inventory.

“We have ready stocks (of air conditioners) and our channel partners (distributors) are also stocked up. The company is waiting for the lockdown to lift,” he added.

Story continues below Advertisement

Carrier Midea India is a joint venture between US-based UTC Climate Control & Security (Carrier brand) and Midea Group of China (Midea brand).

The company has a manufacturing facility in Bawal, Haryana, and a new one in Supa, Maharashtra. Carrier Midea India has exclusive rights to manufacture and sell Carrier and Midea brand air conditioners, Midea brand home appliances and Midea brand commercial ACs in India.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show